Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease.

Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, Harnett MD, Hanauer SB.

Aliment Pharmacol Ther. 2013 Aug;38(3):255-63. doi: 10.1111/apt.12366. Epub 2013 Jun 3.

2.

A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease.

Schölmerich J, Fellermann K, Seibold FW, Rogler G, Langhorst J, Howaldt S, Novacek G, Petersen AM, Bachmann O, Matthes H, Hesselbarth N, Teich N, Wehkamp J, Klaus J, Ott C, Dilger K, Greinwald R, Mueller R; International TRUST-2 Study Group.

J Crohns Colitis. 2017 Apr 1;11(4):390-399. doi: 10.1093/ecco-jcc/jjw184.

3.

Trichuris suis ova therapy for allergic rhinitis does not affect allergen-specific cytokine responses despite a parasite-specific cytokine response.

Bourke CD, Mutapi F, Nausch N, Photiou DM, Poulsen LK, Kristensen B, Arnved J, Rønborg S, Roepstorff A, Thamsborg S, Kapel C, Melbye M, Bager P.

Clin Exp Allergy. 2012 Nov;42(11):1582-95. doi: 10.1111/j.1365-2222.2012.04063.x.

PMID:
23106658
4.

Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.

Summers RW, Elliott DE, Qadir K, Urban JF Jr, Thompson R, Weinstock JV.

Am J Gastroenterol. 2003 Sep;98(9):2034-41.

PMID:
14499784
5.

Use of Trichuris suis ova (TSO) therapy for the treatment of allergy.

Bager P.

Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess. 2013;97:128-9. No abstract available.

PMID:
24912326
6.

Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): study protocol for a randomized controlled trial.

Rosche B, Wernecke KD, Ohlraun S, Dörr JM, Paul F.

Trials. 2013 Apr 25;14:112. doi: 10.1186/1745-6215-14-112.

7.

Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect.

Voldsgaard A, Bager P, Garde E, Åkeson P, Leffers AM, Madsen CG, Kapel C, Roepstorff A, Thamsborg SM, Melbye M, Siebner H, Søndergaard HB, Sellebjerg F, Sørensen PS.

Mult Scler. 2015 Nov;21(13):1723-9. doi: 10.1177/1352458514568173. Epub 2015 Feb 19.

PMID:
25698173
8.

Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial.

Bager P, Arnved J, Rønborg S, Wohlfahrt J, Poulsen LK, Westergaard T, Petersen HW, Kristensen B, Thamsborg S, Roepstorff A, Kapel C, Melbye M.

J Allergy Clin Immunol. 2010 Jan;125(1):123-30.e1-3. doi: 10.1016/j.jaci.2009.08.006. Epub 2009 Oct 3.

PMID:
19800680
9.

Therapeutic potential of larval excretory/secretory proteins of the pig whipworm Trichuris suis in allergic disease.

Ebner F, Hepworth MR, Rausch S, Janek K, Niewienda A, Kühl A, Henklein P, Lucius R, Hamelmann E, Hartmann S.

Allergy. 2014 Nov;69(11):1489-97. doi: 10.1111/all.12496. Epub 2014 Sep 6.

PMID:
25069662
10.

Trichuris suis therapy in Crohn's disease.

Summers RW, Elliott DE, Urban JF Jr, Thompson R, Weinstock JV.

Gut. 2005 Jan;54(1):87-90.

11.

Trichuris suis ova: testing a helminth-based therapy as an extension of the hygiene hypothesis.

Jouvin MH, Kinet JP.

J Allergy Clin Immunol. 2012 Jul;130(1):3-10; quiz 11-2. doi: 10.1016/j.jaci.2012.05.028. Review.

PMID:
22742834
12.

Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial.

Summers RW, Elliott DE, Urban JF Jr, Thompson RA, Weinstock JV.

Gastroenterology. 2005 Apr;128(4):825-32.

PMID:
15825065
13.

Symptoms after ingestion of pig whipworm Trichuris suis eggs in a randomized placebo-controlled double-blind clinical trial.

Bager P, Kapel C, Roepstorff A, Thamsborg S, Arnved J, Rønborg S, Kristensen B, Poulsen LK, Wohlfahrt J, Melbye M.

PLoS One. 2011;6(8):e22346. doi: 10.1371/journal.pone.0022346. Epub 2011 Aug 2.

14.

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.

Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T.

Gut. 2006 Aug;55(8):1138-44. Epub 2006 Feb 21.

15.

Excreted/secreted Trichuris suis products reduce barrier function and suppress inflammatory cytokine production of intestinal epithelial cells.

Hiemstra IH, Klaver EJ, Vrijland K, Kringel H, Andreasen A, Bouma G, Kraal G, van Die I, den Haan JM.

Mol Immunol. 2014 Jul;60(1):1-7. doi: 10.1016/j.molimm.2014.03.003. Epub 2014 Apr 2.

PMID:
24705296
16.

Trichuris suis ova in inflammatory bowel disease.

Schölmerich J.

Dig Dis. 2013;31(3-4):391-5. doi: 10.1159/000354708. Epub 2013 Nov 14. Review.

PMID:
24246995
17.

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ.

N Engl J Med. 1997 Oct 9;337(15):1029-35.

18.

The use of Trichuris suis and other helminth therapies to treat Crohn's disease.

Reddy A, Fried B.

Parasitol Res. 2007 Apr;100(5):921-7. Epub 2007 Jan 6. Review.

PMID:
17206504
19.

Serum levels of brain-derived neurotrophic factor (BNDF) in multiple sclerosis patients with Trichuris suis ova therapy.

Rosche B, Werner J, Benzel FJ, Harms L, Danker-Hopfe H, Hellweg R.

Parasite. 2013;20:55. doi: 10.1051/parasite/2013056. Epub 2013 Dec 19.

20.

Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).

Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, Ponsioen CI, van Dullemen HM, Russel M, van Bodegraven AA, van der Woude CJ.

Gut. 2014 Feb;63(2):292-9. doi: 10.1136/gutjnl-2013-304488. Epub 2013 Mar 23.

PMID:
23525574

Supplemental Content

Support Center